Antwerp

• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• A study to compare the amount of milvexian in blood when given as pediatric and adult tablet formulations, to assess the effect of food inta … Recruiting
  2023-508515-23-00 3 2024-03-19 atherothrombotic and thromboembolic disorders
• ​​Lomustine with or without a second round of brain radiation for the reappearance of glioblastoma Recruiting
  2023-505267-36-00 5 2024-03-15 Glioblastoma
• Efficacy and safety of conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal canc … Recruiting
  2023-506703-26-00 5 2024-02-07 locally advanced rectal cancer
• COLchicine in BElgium in patients with coronary artery disease after Percutaneous Coronary Intervention Recruiting
  2023-505028-74-00 5 2024-01-29 Coronary artery disease
• A Phase 1/2 study of Enzomenib (DSP-5336) in Adult Patients with Acute leukemia Recruiting
  2022-502741-10-00 7 2024-01-26 Acute Leukemia with Mixed Lineage Leukemia (MLL)-rearrangement or Nucl
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-Guided Dose Reduction in Patients with Rheumatoid Arthriti … Recruiting
  2023-506638-59-01 6 2024-01-09 Rheumatoid arthritis
• A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part … Recruiting
  2022-503092-28-00 5 2024-01-08 Relapsed/Refractory Follicular Lymphoma
• Phase 1/2 Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis Recruiting
  2022-502597-16-00 9 2023-10-27 Intermediate or High-risk Primary or Secondary Myelofibrosis
• Semaglutide for the treatment of glucose intolerance in women with prior gestational diabetes Recruiting
  2022-502082-22-00 11 2023-09-14 prediabetes
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Checkpoint Inhibitor i … Recruiting
  2023-504709-35-00 1 2023-08-16 Locally advanced or metastatic solid tumors
• Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting
  2022-502703-30-00 6 2023-06-28 neuroendocrine tumours
• A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting
  2022-501504-95-00 4 2023-06-23 Non-metastatic HER2-positive Breast Cancer
• A phase 1/2 open-label, multicenter study to assess the safety, pharmacokinetics and anti-tumor activity of GTAEXS617 in patients with advan … Recruiting
  2023-508227-13-00 7 2023-06-19 Advanced solid tumors
• Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting
  2022-501710-62-02 6 2023-06-07 Peripheral T-cell lymphoma (PTCL)
• Multicenter randomized controlled clinical trial comparing ebastine and mebeverine as treatment of irritable bowel syndrome Recruiting
  2022-501780-41-00 5 2023-05-17 Irritable Bowel Syndrome
• Preoperative treatment with mFOLFIRINOX (or Gem-Nab-P) +/- isotoxic high-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for borderline … Recruiting
  2022-501181-22-01 4 2023-02-06 Pancreatic adenocarcinoma
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination … Recruiting
  2023-503442-30-00 5 2022-10-14 Multiple Myeloma
• Prevention of postoperative endoscopic disease recurrence in Crohn’s disease: a multicentric study that compares the systematic start of bio … Recruiting
  2022-500311-39-00 6 2022-09-08 Patients with Crohn's disease undergoing surgery and having at least o
• Apremilast Study in Children with Active Juvenile Psoriatic Arthritis Recruiting
  2023-503435-17-00 5 2021-03-31 Juvenile psoriatic arthritis
• Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma Recruiting
  2024-511454-45-00 7 2020-11-09 Relapsed or Refractory Multiple Myeloma

Showing 73–96 of 249 trials